A Safety Study of Sutherlandia Frutescens, a South African Medicinal Plant, in Healthy Adult Volunteers
This study has been completed.
Sponsor:
University of Missouri-Columbia
Collaborators:
University of the Western Cape
Karl Bremer Hospital
Information provided by:
University of Missouri-Columbia
ClinicalTrials.gov Identifier:
NCT00200772
First received: September 12, 2005
Last updated: January 6, 2010
Last verified: January 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study is to investigate the safety of S. frutescens in healthy adult volunteers by assessing liver, kidney, muscle, metabolic, intestinal, cardiac and bone marrow function, as well as physiological and physical status, and to determine whether any of the potential active constituents of the plant is present in the blood of healthy adult volunteers following oral administration of the leaf poweder.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy |
Drug: Sutherlandia frutescens, subspecies microphylla (an herb) |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | A Randomized, Double Blind Placebo Controlled Study to Investigate the Safety of Sutherlandia Frutescens (Subspecies Microphylla) in Health Adult Volunteers. |
Further study details as provided by University of Missouri-Columbia:
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Body weight within 25% of the appropriate weight range
- 12 lead ECG without significant abnormalities
- able to communicate effictively with study personnel
Exclusion Criteria:
- Receiving regular medical treatment
- Hypersensitivity or abnormal reaction to any drugs or herbal products
- Diseases or conditions that might compromise any body system
- History of allergic conditions, such as asthma, urticaria, and eczema
- History or presence of dyspepsia, gastric ulcer or duodenal ulcer
- History of autoimmune disorders, e.g. systemic lupus erythematosus, hemolytic anemia.
- History of psychiatric disorders.
- Intake of any medication within 14 days before start of the study.
- Scheduled to undergo hospitalization for surgery during the study
- Recent history of alcoholism or unwillingness to refrain from excessive alcohol consumption during the study.
- Smokers, who smoke more than 10 cigarettes per day and cannot refreain from smoking during the study period.
- Clinically significant abnormal laboratory results during screening
- Pregnancy or breastfeeding
- Females of childbearing age potential not using medically accepted contraceptive measures, as judged by the investigator.
- Use of any recreational drugs or a history of drug addiction.
- Participation in a clinical study or any investigational product 1 month prior to visit 1 or during the study.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00200772
Locations
| South Africa | |
| Haylene Nell, MBChB | |
| Bellville, Cape Town, Western Cape, South Africa | |
Sponsors and Collaborators
University of Missouri-Columbia
University of the Western Cape
Karl Bremer Hospital
Investigators
| Principal Investigator: | Haylene Nell, MBChB | Tiger Trial Centre, Karl Bremmer Hospital, Tygerberg, South Africa |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00200772 History of Changes |
| Other Study ID Numbers: | R21 AT001944-01, R21AT001944-01 |
| Study First Received: | September 12, 2005 |
| Last Updated: | January 6, 2010 |
| Health Authority: | United States: Federal Government |
Keywords provided by University of Missouri-Columbia:
|
Sutherlandia Frutescens Normal volunteers |
ClinicalTrials.gov processed this record on May 16, 2013